Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Dale Terasaki

Concepts (80)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Alcoholism
6
2024
830
2.810
Why?
Buprenorphine
6
2026
197
2.360
Why?
Substance Withdrawal Syndrome
4
2023
185
2.290
Why?
Opioid-Related Disorders
5
2026
634
1.730
Why?
Naltrexone
4
2024
114
1.730
Why?
Referral and Consultation
3
2026
881
1.270
Why?
Podiatry
1
2026
5
0.950
Why?
Substance-Related Disorders
2
2026
1100
0.930
Why?
Ibogaine
1
2026
9
0.930
Why?
Addiction Medicine
1
2026
14
0.930
Why?
Inpatients
4
2026
540
0.910
Why?
Methadone
3
2026
130
0.890
Why?
Psychology, Clinical
1
2025
17
0.870
Why?
Opiate Substitution Treatment
4
2026
195
0.860
Why?
Psychology
1
2025
85
0.840
Why?
Hallucinogens
1
2026
112
0.790
Why?
Professional Role
1
2025
172
0.790
Why?
Hospitalization
2
2023
2475
0.740
Why?
Ketamine
1
2022
144
0.660
Why?
Cocaine-Related Disorders
1
2022
132
0.630
Why?
Tramadol
1
2020
17
0.620
Why?
Cocaine
1
2022
162
0.610
Why?
Patient Care Team
1
2025
701
0.580
Why?
Drug Substitution
1
2019
62
0.580
Why?
Analgesics, Opioid
4
2023
1221
0.550
Why?
Automobiles
1
2017
18
0.510
Why?
Transportation
1
2017
54
0.490
Why?
Narcotic Antagonists
3
2023
210
0.450
Why?
Internship and Residency
1
2026
1281
0.440
Why?
Emigrants and Immigrants
1
2017
160
0.410
Why?
Humans
17
2026
146342
0.290
Why?
Alcohol Drinking
2
2024
850
0.240
Why?
Violence
1
2009
275
0.220
Why?
Male
9
2026
73396
0.220
Why?
Exercise
1
2017
2213
0.210
Why?
Middle Aged
6
2024
36619
0.210
Why?
Adult
7
2023
41087
0.210
Why?
Disulfiram
1
2024
15
0.200
Why?
Deltoid Muscle
1
2023
6
0.190
Why?
Phenobarbital
1
2023
22
0.190
Why?
Students
1
2009
649
0.190
Why?
Injections, Intramuscular
1
2023
140
0.190
Why?
Delayed-Action Preparations
1
2023
192
0.180
Why?
Chest Pain
1
2022
100
0.170
Why?
Drug Overdose
1
2026
377
0.170
Why?
Fentanyl
1
2022
126
0.160
Why?
Attitude
1
2023
253
0.160
Why?
Depression
1
2009
1575
0.140
Why?
Medication Adherence
1
2023
535
0.140
Why?
Self Report
1
2023
870
0.140
Why?
Logistic Models
2
2017
2126
0.140
Why?
Feasibility Studies
1
2022
1135
0.130
Why?
Acculturation
1
2017
55
0.120
Why?
Pilot Projects
1
2022
1888
0.120
Why?
Patient Readmission
1
2022
778
0.120
Why?
Cross-Sectional Studies
2
2023
5899
0.120
Why?
Young Adult
3
2022
14330
0.120
Why?
Surveys and Questionnaires
2
2023
6073
0.110
Why?
Patient Discharge
1
2022
997
0.110
Why?
Dose-Response Relationship, Drug
1
2019
2022
0.110
Why?
Female
5
2026
79499
0.100
Why?
Residence Characteristics
1
2017
385
0.100
Why?
Colorado
1
2023
4595
0.100
Why?
Aged
2
2023
26432
0.090
Why?
Socioeconomic Factors
1
2017
1327
0.090
Why?
Walking
1
2017
546
0.090
Why?
Emergency Service, Hospital
1
2023
2363
0.080
Why?
Adolescent
2
2022
22557
0.080
Why?
Ethiopia
1
2009
43
0.070
Why?
Anger
1
2009
55
0.070
Why?
Confidence Intervals
1
2009
329
0.070
Why?
Developing Countries
1
2009
312
0.060
Why?
Risk-Taking
1
2009
321
0.060
Why?
Odds Ratio
1
2009
1077
0.060
Why?
Multivariate Analysis
1
2009
1543
0.050
Why?
Incidence
1
2009
2936
0.040
Why?
Buprenorphine, Naloxone Drug Combination
1
2021
13
0.040
Why?
Severity of Illness Index
1
2009
2921
0.040
Why?
United States
1
2017
16136
0.040
Why?
Risk Assessment
1
2009
3712
0.040
Why?
Terasaki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)